Dynamic telecytopathology of on site rapid cytology diagnoses for pancreatic carcinoma by Kim, Burton et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
CytoJournal
Open Access Research
Dynamic telecytopathology of on site rapid cytology diagnoses for 
pancreatic carcinoma
Burton Kim*1, David C Chhieng2, David R Crowe2, Darshana Jhala2, 
Nirag Jhala2, Thomas Winokur2, Mohamad A Eloubeidi2,3 and 
Isam E Eltoum2
Address: 1Scripps Green Hospital/Clinic, Department of Pathology, La Jolla, California, USA, 2University of Alabama at Birmingham, Department 
of Pathology, Birmingham, Alabama, USA and 3University of Alabama at Birmingham, Department of Gastroenterology, Birmingham, Alabama, 
USA
Email: Burton Kim* - kim.burton@scrippshealth.org; David C Chhieng - dchhieng@uab.edu; David R Crowe - drcrowe@uab.edu; 
Darshana Jhala - djhala@uab.edu; Nirag Jhala - njhala@uab.edu; Thomas Winokur - tinokur@uab.edu; 
Mohamad A Eloubeidi - eloubeidi@uab.edu; Isam E Eltoum - ieltoum@uab.edu
* Corresponding author    
Abstract
Background: Diagnosis of pancreatic lesions can be accurately performed by endoscopic ultrasound guided fine needle
aspiration (EUS-FNA) with onsite cytopathologists to assess specimen adequacy and to determine a preliminary
diagnosis. Considerable time is needed to perform on-site assessments. This takes away work time of cytopathologists
and prohibits them from serving remote locations. It is therefore logical to ask if real-time telecytopathology could be
used to assess specimen adequacy and if telecytopathology diagnosis has the same level of agreement to the final diagnosis
as that of onsite evaluation. In this study, we compare agreement between cytodiagnoses rendered using
telecytopathology with onsite and final interpretations.
Method: 40 Diff-Quik-stained EUS-FNA were re-evaluated retrospectively (patient ages 31–62, 19:21 male:female, 15
non-malignant lesions, 25 malignant lesions as classified by final diagnosis). Each previously assessed by a cytopathologist
and finally reviewed by the same or different cytopathologist. Blinded to the final diagnosis, a resident pathologist re-
screened all slides for each case, selected a slide and marked the diagnostic cells most representative of the lesion.
Blinded to the diagnosis, one cytopathologist assessed the marked cells through a real time remotely operated
telecytopathology system (MedMicroscopy). Diagnosis and time spent were recorded. Kappa statistic was used to
compare agreements between telecytopathology vs. original onsite vs. final diagnoses.
Results: Time spent for prescreening ranged from 1 to 5 minutes (mean 2.6 +/- 1.3 minutes) and time spent for
telecytopathology diagnosis ranged from 2–20 minutes (mean 7.5 +/- 4.5 minutes). Kappa statistics, K, was as follows:
telecytopathology versus onsite diagnosis K, 95% CI = 0.65, 0.41–0.88, for telecytopathology versus final K, 95% CI =
0.61, 0.37–0.85 and for onsite diagnosis versus final K, 95% CI = 0.79, 0.61–0.98. There is no significant difference in
agreement between onsite and telecytopathology diagnoses. Kappa values for telecytopathology were less than onsite
evaluation when compared to the final diagnosis; however, the difference was not statistically significant.
Conclusion: This retrospective study demonstrates the potential use of telecytopathology as a valid substitute for
onsite evaluation of pancreatic carcinoma by EUS-FNA.
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Background
Pancreatic adenocarcinoma is a swift and deadly cancer
whereupon an accurate diagnosis can be challenging,
since many of the clinical and pathologic features overlap
with those of non-malignant inflammatory lesions. Endo-
scopic ultrasound guided fine needle aspiration (EUS-
FNA) has proven to be a highly sensitive and specific
method to detect early malignant pancreatic lesions and
to provide accurate pre-operative staging for the treatment
of pancreatic adenocarcinoma [1,2]. EUS-FNA entails
imaging of the pancreas from vantages of the duodenum
and stomach. A cytology specimen is then aspirated
through insertion of a fine needle. A cytopathologist can
then examine the cells after appropriate processing of the
tissue [3-8]. With smaller pancreatic lesions, the diagnos-
tic utility of EUS-FNA exceeds that of extracorporeal ultra-
sound and computed tomographic aspirations [1,7].
A crucial component for the success of EUS-FNA is to have
the cytopathologist examine the cellular aspirate onsite at
bedside. This practice ensures accurate and consistent
results for delivering a preliminary onsite diagnosis as
well as ensuring that the specimen aspirated is adequate
for cytological diagnosis.
When the cytopathologist participates in EUS-FNA in this
manner, aconflict arises in the larger context of the cytopa-
thology practice. For the cytopathologist, actively partici-
pating in an EUS-FNA procedure means having to
interrupt one's routine work flow which results in tempo-
rarily leaving cases undiagnosed at the microscope, delay-
ing laboratory management issues, and postponing
academic administrative duties.
This practice has currently become a management issue of
interest. In fact, the cost/benefit ratio of performing onsite
rapid diagnoses have been scrutinized in a study by Lay-
field et al. where it was reported that an average fifty dollar
loss per rapid onsite cytologic diagnosis performed was
demonstrated when taking into account Medicare reim-
bursement rates (88172). Onsite rapid diagnoses
adversely impacted time management for cytopatholo-
gists and subsequently lead to inadequate compensation
[9].
Telepathology may reverse these findings. Telepathology
has long been proposed and used to bring consultative
pathology services closer by eliminating physical dis-
tances by delivering diagnoses in real-time [10]. Numer-
ous studies have been performed validating use of
telepathology by both static and dynamic systems for var-
ious surgical pathology and cytology specimens [11-17].
We propose using a dynamic telecytopathology method
to eliminate traveling time, which would make better use
of a cytopathologist's time and improve the cost/benefit
ratio of performing rapid interpretations. Dynamic telepa-
thology consists of a remotely operated robotic micro-
scope that transmits digital microscopic images of glass
slides from one geographic location to another in real
time.
In this study we investigate the use of a dynamic telepa-
thology system with EUS-FNA pancreatic specimens to
determine if rapid diagnoses made by telepathology are
just as accurate as compared to being onsite and to dem-
onstrate an improvement of time management for the
cytopathologist to further increase productivity.
Methods
Telepathology system
MedMicro System (Trestle Corporation of Irvine, CA) was
used for our dynamic telepathology hardware and soft-
ware. This system consists of remotely operated robotics
at the stage, objective, and focus levels incorporated into
an Olympus BX41 microscope. This robotic system is con-
nected to a standard PC computer (requirements: Pen-
tium III 450 MHz, Windows 2000, 128 MB RAM, 50 MB
of free Hard Drive space, 1280 × 1024 Display). At an off-
site location in the cytopathologist office, remote opera-
tion was performed through a standard PC
computer(requirements: Pentium 200 MMX, Windows
98/NT/2000/ME, 32 MB RAM, 10 MB of free Hard Drive
space, 1024 × 768 Display) through Internet Protocol
(IP). The included MedMicro Viewer software also allows
full navigation of the slide, including control of objective,
focus, and illumination. This system enables transfer of
24-bit images to be interpreted in a dynamic fashion in
real-time (see figures 1, 2, 3).
Prior to initiating our study, an informal training session
was conducted, which entailed independent familiariza-
tion with the MedMicro system that covered the basics of
operation. This was regarded as minimal, since many of
the functions are intuitive with point-and-click features.
Case materials
40 pancreatic lesions diagnosed by EUS-FNA methods
were retrieved. The patients' ages ranged from 31 to 62
years. There were 19 males and 21 females. Each case had
been previously assessed by other cytopathologists and
finally reviewed by the same or different attending
cytopathologist. By previous final diagnosis, 15 cases were
non-malignant (benign, inflammation, scant) and 25
were malignant (carcinoma and suspicious for carci-
noma). Cover-slipped Diff-Quik-stained slides (DQ)
from all cases were reviewed by a pathology resident-in-
training (BK) who was blinded to the final diagnoses.
Cases to be examined were created by selecting one or few
(<3 slides for any given case) representative slides markedCytoJournal 2006, 3:27 http://www.cytojournal.com/content/3/1/27
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by BK to highlight areas to be then reviewed through the
MedMicro system.
Reinterpretation and specimen preparation
The selected pre-screened DQ slides were randomized to
be presented in an unknown fashion through the MedMi-
cro system for an offsite attending cytopathologist (IAE).
The selected slide(s) was placed onto the stage of the
robotic microscope by BK and an initial whole slide scan
was performed, encompassing approximately two min-
utes for each case. Once the slide has been initially pre-
scanned, the cytopathologist then re-evaluated the cases
by remotely controlling and reviewing the prescreened,
randomized cases. The slide could be magnified, focused,
and moved at the discretion of the offsite cytopathologist.
Diagnoses were then rendered for each case using catego-
ries of negative for malignancy, positive for malignancy,
and suspicious for malignancy. For this study the
cytopathologist was also blinded to the original demo-
graphics and diagnoses of these cases (see figure 4).
Statistics
Data was collected and collated using an Excel spread-
sheet. Kappa statistic was used to compare agreements
between telepathology versus original onsite and versus
final diagnoses. Times were recorded with standard calcu-
lations of averages and standard deviation.
Results
Using the MedMicro system, the attending cytopatholo-
gist diagnosed 18 of the 40 cases negative for carcinoma,
16 positive for carcinoma, and 6 suspicious for carci-
noma. The previous onsite preliminary diagnoses had
been 18 for carcinoma, 16 for benign/scant/inflamma-
Client Side Figure 1
Client Side. Figure 1 shows the initial scan of a slide showing the whole slide. Time taken to  perform overall scan averages 2 
minutes when scanning with 4x objective. Individual  squares are digital snapshots at a 24x16 grid, encompassing the entire 
slide.  CytoJournal 2006, 3:27 http://www.cytojournal.com/content/3/1/27
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tion, and 6 for suspicious. Final diagnoses of the same
cases showed 23 for carcinoma, 15 for benign/inflamma-
tion, and 2 for suspicious. We combined these findings
into two categories of benign and malignant while defin-
ing carcinoma and suspicious for carcinoma as both
malignant. The remainder was defined as benign. With
these two categories established, Kappa statistic calcula-
tions were performed. Kappa for telepathology versus
onsite rapid diagnosis was 0.65, 0.41–0.88 (K, 95% CI).
Kappa for telepathology versus final diagnosis was 0.61,
0.37–0.85 (K, 95% CI). Kappa for onsite rapid diagnosis
versus final diagnosis was 0.79, 0.61–0.98 (K, 95% CI).
Time spent by the resident-in-training for prescreening
and selecting example slides from each of the 40 cases
ranged from 1 to 4 minutes (mean 2.6 ± 1.3 minutes).
Overall, less time was spent on those cases with fewer
original slides to preview and more time was needed to
prescreen those cases with more original slides. Time
spent to make a telepathology diagnosis ranged from 2–
20 minutes (mean 7.5 ± 4.5 minutes). This time does not
include the initial whole slide pre-scan, which would add
two minutes to each case. The longer telepathology diag-
nostic times were noted in the beginning at the start of
this study, and as our study progressed, the time needed
to reach a diagnosis decreased.
Overall, the quality of images was considered excellent as
surveyed by the remote cytopathologist. The effort to
operate the robotic microscope from an offsite location
was also noted to be non-problematic. Occasional fine-
tuning was needed at the microscope site for initial setup
of analog light intensity and condenser position. Once the
Pre-screened Region Figure 2
Pre-screened Region. Figure 2 shows further magnification of the initial whole slide scan at a pre-screened  location marked 
with two black ink dots.CytoJournal 2006, 3:27 http://www.cytojournal.com/content/3/1/27
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microscope was configured to optimally view slides, no
further adjustments were performed.
Discussion
EUS-FNA is superior to other methods in overall cost/ben-
efit aspects for diagnosing pancreatic carcinomas [18,19].
Together with both the endoscopist and cytopathologist
onsite, EUS-FNA provides high cellular yield (86%–98%),
high sensitivity (77%–95%) and high specificity (96%–
100%). Overall accuracy (79%–97%) has been shown for
the diagnosis of malignant neoplasia. Also, previous stud-
ies have shown a Kappa value of 0.88 when comparing
onsite EUS-FNA rapid diagnoses to offsite final diagnoses
for all pancreatic lesions. With regards to diagnoses of car-
cinoma, a kappa value of 1.0 was also reported [4,7,18-
21].
A major reason why EUS-FNA is so successful is because
an onsite cytopathologist is present to process and inter-
pret. It has been shown that specimen yield is better
whenever a cytopathologist is onsite versus not being
present [2,22], but postponing other duties to be onsite at
a EUS-FNA comes at a cost to the cytopathologist. Our
study suggests that telepathology is an appropriate surro-
gate for being onsite, while saving time.
In support of the previous studies noting the high accu-
racy of EUS-FNA, we found similar results in our study
through use of our dynamic telepathology system. We
also calculated a kappa value of 0.79 when comparing
onsite EUS-FNA rapid diagnoses to offsite final diagnoses
for all pancreatic lesions, benign and malignant. Kappa
value was also 1.0 with carcinoma diagnoses.
Diagnosis Figure 3
Diagnosis. Figure 3 shows an even higher magnification of the pre-screened region. Large  atypical cells with marked pleomor-
phism, abundant cytoplasm with vacuolization,  discohesiveness, and disruption of epithelial architecture are all features seen 
here that  illustrate the telepathology diagnosis of carcinoma.CytoJournal 2006, 3:27 http://www.cytojournal.com/content/3/1/27
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Since statistically our control group agreed with previous
study results, we deemed our comparison data (onsite
rapid vs. final) reliable to use when investigating the effec-
tiveness of telepathology. The Kappa value of telepathol-
ogy diagnoses with that of the final diagnoses was 0.61
[sensitivity = 0.86 (0.76–1.00), specificity = 0.67 (0.45–
0.88), PPV = 0.76 (0.59–0.93), NPV = 0.80 (0.60 – 1.00).
When comparing onsite rapid (Kappa-rapid = 0.79) and
offsite telepathology (Kappa-telepathology = 0.61) as ref-
erenced to the final diagnoses, no significant difference in
agreement was noted.
Indeed Kappa values for telecytopathology were less than
onsite evaluation when compared to the final diagnosis,
even though this difference was not statistically signifi-
cant. There are several possible reasons for this. Final diag-
noses had the advantages of Papanicolaou stain slides,
hematoxylin/eosin stained cell block preparations, and
other ancillary tests such as flow cytometry to aid in a
more comprehensive diagnosis. Originally, all the DQ
slides in these cases were created onsite and the onsite
cytopathologist had the advantage of looking through all
the DQ slides of a given case to aid in the onsite rapid
diagnosis.
For our telepathology arm of this study the cases were pre-
screened and only one to three slides were selected from
each case. Many cases were limited to one selected DQ
slide with the assumption that the single slide would be
truly representative for the entire case. Therefore, pre-
Work Flow Figure 4
Work Flow. Figure 4 shows the telepathology workflow which starts at the FNA aspiration by the  gastroenterologist. The 
specimen is then prepared and corresponding slides are prescreened.  Real-time interpretation of the slides can then be per-
formed from single or  multiple end user cytopathologists who may diagnosis as solo or as a consensus  group. Results can then 
be given by telephone or intercom to the gastroenterologist  onsite. This work diagram can be implemented in most any geo-
graphic situation.CytoJournal 2006, 3:27 http://www.cytojournal.com/content/3/1/27
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screening and selecting the single most pertinent slide
weighed heavily upon the skill and experience of the pre-
screener, BK, whose job was to mark any atypical cells. In
this study, it may be noteworthy to mention that BK had
no prior formal cytology training at the time of pre-screen-
ing.
Familiarity with the telepathology system and being
accustomed to viewing diagnostic images on a computer
monitor may also have played a role in a decreased corre-
lation. Many of the false-positives and false-negative cases
rendered through the telepathology method were made
early within the 40 cases seen. When the cytopathologist
became more accustomed to the MedMicro system, we
noted fewer discordant diagnoses as well as shorter diag-
nosis times.
Other studies with telepathology have been performed
with success, detailing the utility of telepathology with
cytology in other organs, such as breast, gastrointestinal,
and gynecological [23-28]. Most of these studies involved
static telepathology methods where upon a diagnosis is
made on one or few images. Marchevsky et al has explored
with encouraging results the use of static telepathology
techniques on EUS-FNA pancreatic carcinoma specimens
[29]. The drawback of a static telepathology method is the
image sampling. Is the snapshot truly representative for
the whole slide? For cytology, cells are often arranged in a
three dimensional manner and the examination of multi-
ple focal planes are crucial to an accurate diagnosis. Also,
cells are spread throughout the slide, and scanning an
entire slide is necessary to ensure that all relevant cells are
examined.
A common bottleneck for both static and dynamic telepa-
thology is data processing and transmission speeds. Most
institutions operate on a T1 speed line (1.544 Mbps)
Microscopic digital images of surgical pathology and
cytology are complex and indeed generate large file sizes,
which lead to transmission times too long to be deemed
useful.
Four other main issues come into play regarding use of a
dynamic telepathology system as a substitute for onsite
rapid diagnosis of EUS-FNA cases. The first issue regards
accuracy. When comparing a cytopathologist using telepa-
thology coupled with an onsite prescreener versus a regu-
lar onsite cytopathologist, our study showed statistically
non-significant decrease in observed Kappa values
between telepathology and onsite rapid diagnoses. Even
though Kappa for telepathology versus final diagnosis was
less than that of onsite rapid values, it still demonstrates
how telepathology can be an appropriate substitution. In
fact, combined with improved onsite pre-screening and
competency in telepathology utilization, accuracy should
only increase to better match those of onsite evaluations.
However, additional prospective studies on this proposal
must be performed.
The second issue regards the actual benefit of preventing
time from being spent away from routine office duties. For
the telepathology method when summing the pre-screen
time, scan time, and diagnosis time, an average total of 12
minutes is needed to perform a telepathology rapid diag-
nosis. An average of 7.5 minutes of this total is actually
spent by the cytopathologist in rendering a rapid diagno-
sis through telepathology. This is much shorter than the
time spent for the cytopathologist who must travel to the
site and wait during the dead time between aspirations,
which can total to average over 30 minutes [30]. Also,
with the time saved by the telepathology cytopathologist,
routine office work can continue with improved time
management.
The third issue regards to loss of personal contact and
communication with the clinician that may damage
patient care. Our study suggests that it is not essential for
a cytopathologist to be physically present at bedside for
rapid diagnoses. However, this does not mean all or any
interaction with the endoscopist is sacrificed. Indeed, a
crucial component to our telepathology method is com-
munication. Telepathology is highly interactive where
multiple simultaneous users can access it to share their
thoughts on each case. The ability for mass communica-
tion/teaching beyond any distance is the major advantage
gained for the sacrifice of the physical interaction between
the pathologist and clinician. In fact, telepathology
advances communication so that pathologists can reach
out to more clinicians, thereby improving patient care as
a whole.
The fourth issue regards startup capital costs. Even though
the cytopathologist is not physically present onsite, our
dynamic telepathology method still requires a member
with sufficient experience to pre-screen and prepare slides.
Costs of this member with expertise would certainly need
to be included when assessing the overall cost/benefit
ratio of this telepathology method. Current thought is
that onsite rapid diagnosis of EUS-FNA cases entails a loss
in revenue, resulting in an unprofitable use of a
cytopathologist's time, since average time taken during
one onsite event may average to over an hour [30]. Also,
startup costs of additional equipment and time taken to
learn a new method are both issues to take into account to
evaluate the overall cost effectiveness of telepathology.
However, once a system is in place and efficient compe-
tency is achieved, a telepathology practice can be more
cost effective and lead to more opportunities.CytoJournal 2006, 3:27 http://www.cytojournal.com/content/3/1/27
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Conclusion
EUS-FNA of pancreatic malignancies has been proven to
be accurate and cost effective, especially when an onsite
cytopathologist is present. Our study demonstrates that
telecytopathology has statistically equal accuracy to onsite
rapid examinations. It also emphasizes the additional
advantages of time and cost savings of using telecytopa-
thology with EUS-FNA. Telecytopathology is an appropri-
ate substitute for the onsite evaluation of pancreatic EUS-
FNA and aids cytopathologists to use time more effi-
ciently.
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